Your browser doesn't support javascript.
loading
Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation.
Manciu, Marian; Hosseini, Sorour; Di Desidero, Teresa; Allegrini, Giacomo; Falcone, Alfredo; Bocci, Guido; Kirken, Robert A; Francia, Giulio.
Afiliación
  • Manciu M; Department of Physics, University of Texas at El Paso, El Paso, TX, 79968, USA.
  • Hosseini S; Department of Physics, University of Texas at El Paso, El Paso, TX, 79968, USA.
  • Di Desidero T; Department of Physics, University of Texas at El Paso, El Paso, TX, 79968, USA.
  • Allegrini G; Department of Physics, University of Texas at El Paso, El Paso, TX, 79968, USA.
  • Falcone A; Division of Pharmacology, Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy.
  • Bocci G; Division of Pharmacology, Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy.
  • Kirken RA; Division of Medical Oncology, Pontedera Hospital, Azienda USL of Pisa, Pontedera, Italy.
  • Francia G; Division of Medical Oncology, Pontedera Hospital, Azienda USL of Pisa, Pontedera, Italy.
Future Sci OA ; 4(10): FSO346, 2018 12.
Article en En | MEDLINE | ID: mdl-30450233
ABSTRACT

Aim:

To construct classification scores based on a combination of cancer patient plasma biomarker levels, for predicting progression-free survival.

Methods:

The approach is based on the optimization of the biomarker cut-off values, which maximize the statistical differences between the groups with values lower or larger than the cut-offs, respectively. An intuitive visualization of the quality of the classification score is also proposed.

Results:

Even if there are only weak correlations between individual biomarker levels and progression-free survival, scores based on suitably chosen combination of three biomarkers have classification power comparable with the Response Evaluation Criteria in Solid Tumors criteria classification of response to treatments in solid tumors.

Conclusion:

Our approach has the potential to improve the selection of the patients who will benefit from a given anticancer treatment.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Future Sci OA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Future Sci OA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos